Biofil Chemicals & Pharmaceuticals per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹0.30₹1.71₹0.34₹0.44₹0.29
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹0.30₹1.71₹0.34₹0.44₹0.29
₹13.25₹13.25₹11.54₹11.19₹10.63
₹21.08₹17.45₹20.53₹24.60₹18.46
—−₹0.37−₹1.18₹1.47−₹0.07
−₹0.49−₹0.49−₹1.24₹1.46−₹0.08
1.61.61.61.61.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹47.6 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS0.290.440.341.710.30
Diluted EPS0.290.440.341.710.30
Book Value per Share10.6311.1911.5413.2513.25
Revenue per Share18.4624.6020.5317.4521.08
Cash Flow per Share-0.071.47-1.18-0.37—
Free Cash Flow per Share-0.081.46-1.24-0.49-0.49
Shares Outstanding (cr)1.61.61.61.61.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.